US approves promising preventive HIV treatment
The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injvirection, for preventing HIV infection in adults and adolescents at high risk of contracting the deadly virus. Lenacapavir proved nearly 100% effective at preventing HIV in large trials last year, raising new hope of interrupting transmission of the virus that infects 1.3 million people a year.
The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injvirection, for preventing HIV infection in adults and adolescents at high risk of contracting the deadly virus. Lenacapavir proved nearly 100% effective at preventing HIV in large trials last year, raising new hope of interrupting transmission of the virus that infects 1.3 million people a year.
